Q2 2014 13F Holders as of 6/30/2014
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
8.11M
-
Shares change
-
+1.22M
-
Total reported value, excl. options
-
$349M
-
Value change
-
+$52.8M
-
Put/Call ratio
-
1.28
-
Number of buys
-
69
-
Number of sells
-
-30
-
Price
-
$43.07
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q2 2014
105 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q2 2014.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.11M shares
of 27.8M outstanding shares and own 29.2% of the company stock.
Largest 10 shareholders include FMR LLC (2M shares), Consonance Capital Management LP (1.55M shares), EAGLE ASSET MANAGEMENT INC (802K shares), SENZAR ASSET MANAGEMENT, LLC (255K shares), BlackRock Fund Advisors (255K shares), WALL STREET ASSOCIATES (219K shares), GLENMEDE TRUST CO NA (188K shares), VANGUARD GROUP INC (180K shares), INSIGHT CAPITAL RESEARCH & MANAGEMENT INC (158K shares), and CADENCE CAPITAL MANAGEMENT LLC (133K shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.